Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?

Radiation Oncology Division, Breast Health Center, Naval Medical Center San Diego, San Diego, CA, USA.
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 07/2008; 100(11):773-83. DOI: 10.1093/jnci/djn148
Source: PubMed

ABSTRACT Despite nearly two decades of research investigating the use of dietary antioxidant supplementation during conventional chemotherapy and radiation therapy, controversy remains about the efficacy and safety of this complementary treatment. Several randomized clinical trials have demonstrated that the concurrent administration of antioxidants with chemotherapy or radiation therapy reduces treatment-related side effects. Some data indicate that antioxidants may protect tumor cells as well as healthy cells from oxidative damage generated by radiation therapy and some chemotherapeutic agents. However, other data suggest that antioxidants can protect normal tissues from chemotherapy- or radiation-induced damage without decreasing tumor control. We review some of the data regarding the putative benefits and potential risks of antioxidant supplementation concurrent with cytotoxic therapy. On the basis of our review of the published randomized clinical trials, we conclude that the use of supplemental antioxidants during chemotherapy and radiation therapy should be discouraged because of the possibility of tumor protection and reduced survival.

Download full-text


Available from: Jeffrey B. Blumberg, Aug 21, 2015
    • "ALDH activity can be inhibited pharmacologically by 4-diethylaminobenzaldehyde (DEAB) (Fig. 1). Because chemotherapy is known to induce oxidative stress [44], it is possible that inhibition of ALDH activity using DEAB may sensitize ALDH hi CSC to therapy through enhanced exposure to ROS and induction of apoptosis [41]. We were able to increase susceptibility of colorectal cancer cells (HT-29) to chemotherapy after incubation with DEAB in our preliminary study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant tumours consist of heterogeneous populations of tumour cells. Cancer stem cells (CSC) represent a population of cells within a tumour with highly tumorigenic and chemoresistant properties. These cells may be identified by the expression of CSC markers. There are several key stem cells markers specified for colon cancer: CD133, CD44, ALDH1, ALCAM. These days, a major obstacle to effective cancer management is development of a multidrug resistance (MDR). The principal mechanism responsible for development of MDR phenotype is the over-expression of ABC transporters. Tumours and relapsing tumours after therapy are drived by subpopulations of tumour cells with aggressive phenotype resistant to chemotherapeutics. These cells are called CSC or tumour-initiating cells (TIC). Here we outline recent information about MDR of colon cancer and CSC markers. We have focused on novel therapeutic strategies which have been developed to prevent or overcome MDR. One such strategy is a combination of chemotherapy and modulators of MDR pumps or chemotherapy and monoclonal antibodies against vascular endothelial growth factor VEGF. Colon cancer is characterized by the presence of colon CSC expressing specific stem cell markers. The divergent presence of these markers can help to adjust personalized therapy. The review provides a detailed overview of resistance of colon cancer cells and discusses how the presence of CSC markers can influence therapy and prognosis of patients.
    Biomedecine [?] Pharmacotherapy 10/2014; 68(8). DOI:10.1016/j.biopha.2014.10.019 · 2.11 Impact Factor
  • Source
    • "However, the evidence from observational epidemiologic studies on vitamin C intake and survival following breast cancer diagnosis is not consistent, with dietary vitamin C intake reported to reduce the risk of mortality in some studies (Rohan et al, 1993; Ingram, 1994; Jain et al, 1994; Fleischauer et al, 2003; McEligot et al, 2006) and no association in other studies (Zhang et al, 1995; Hebert et al, 1998; Holmes et al, 1999; Saxe et al, 1999; Saquib et al, 2011). In addition, the safety of oral vitamin C supplements following cancer diagnosis is not clear (Lawenda et al, 2008) and few studies have examined vitamin C supplements in relation to breast cancer survival (Greenlee et al, 2009; Nechuta et al, 2011; Greenlee et al, 2012). The aim of this study was to investigate whether pre-diagnosis dietary vitamin C intake was associated with total and breast cancer-specific mortality among women diagnosed with invasive breast cancer in the Swedish Mammography Cohort (SMC). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Vitamin C may influence cancer progression through its antioxidant properties. However, the evidence from observational epidemiologic studies on vitamin C intake and survival following breast cancer diagnosis is not consistent, and the safety of vitamin C supplements following breast cancer diagnosis has not been extensively studied. Methods: Using a food-frequency questionnaire we investigated whether vitamin C intake was associated with survival among 3405 women diagnosed with invasive breast cancer in the Swedish Mammography Cohort. Results: From 1987–2010, there were 1055 total deaths with 416 deaths from breast cancer. Women in the highest quartile of pre-diagnosis vitamin C intake had an adjusted HR (95% CI) of breast cancer death of 0.75 (0.57–0.99) compared with those in the lowest quartile (Ptrend=0.03). There was a borderline significant association between vitamin C intake and total mortality (HR=0.84; 95% CI=0.71–1.00; Ptrend=0.08). Among 717 breast cancer cases for whom post-diagnosis supplement use was available, there was no association between vitamin C supplement use (≈1000 mg) and breast cancer-specific mortality (HR=1.06; 95% CI=0.52–2.17). Conclusion: Our findings suggest that dietary vitamin C intake before breast cancer diagnosis may be associated with breast cancer survival. In addition, post-diagnosis vitamin C supplementation at the level observed in our population was not associated with survival.
    British Journal of Cancer 06/2013; 109(1). DOI:10.1038/bjc.2013.269 · 4.82 Impact Factor
  • Source
    • "Gradually by novel discoveries in physiology and pathology of cancer cells via modern and developed techniques, more findings challenge the administration of antioxidants during radiation and chemotherapy for cancer. Lastly, some clinical trials have revealed both anticancer and cancerocid effects of antioxidants, in which tumorigenesis activity was related to high risk patients including smokers and alcohol consumers, whereas anticancer activity was found in patients during chemotherapy or radiotherapy (Lawenda et al., 2008; Omenn et al., 1996). The question arises: " Why does an oncologist recommend avoiding antioxidants in cancer treatment? "
    [Show abstract] [Hide abstract]
    ABSTRACT: There are a number of intrinsic (e.g. oncogenes) and extrinsic (e.g. radiation and inflammation) factors, which may arise in reactive oxygen species (ROS), resulting in DNA instability and then cancer. In this situation, initial cancerous cells would balance the harmful effects of ROS by switching on the protective effects in a longstanding manner. In normal conditions, ROS have important role in signal transduction and gene transcription, nevertheless, ROS may act as a trigger for carcinogenesis via persistent DNA injuries as well as mutations in p53 such as conditions observed in skin, hepatocellular, and colon cancers. Some compounds like paclitaxel are able to attack cancer cells through generation of ROS or interfering with ROS metabolism, while there are a few anti-angiogenesis compounds without toxicity such as endostatin, which act as anti-neoplastic only together with another chemotherapeutic drug. Furthermore, some anti-cancer agents like piperlongumine bind to the active sites of several key cellular antioxidants including glutathione S transferase and carbonyl reductase 1 only in the cancer cells. Although the natural antioxidants can alone or in combination to the diet provide some benefits for chemoprevention, their position in cancer therapy, especially initial stages of carcinogenesis are breaking down. On the other hand antioxidants can promote the survival of detached cells from extra cellular medium playing dual activities with respect to tumorigenesis through inhibition of tumorigenesis by preventing oxidative injuries to DNA and otherwise maintenance of tumor by promoting cell survival via metabolic rescue. Hopefully, more details of antioxidant and anti-neoplastic mechanisms become clear day by day, which have made researchers to renew the strategy for designing cancer prevention or treatment.
    Toxicology and Applied Pharmacology 05/2013; 271(1). DOI:10.1016/j.taap.2013.05.004 · 3.63 Impact Factor
Show more